Ampio Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;'>AP</div>
AMPE -- USA Stock  

USD 1.55  0.05  3.33%

While some baby boomers are getting worried about healthcare space, we are going to digest both, Ampio Pharmaceuticals and Precision BioSciences as potential shorter-term investments. We are going to discuss some of the competitive aspects of both Ampio and Precision.
Published over three weeks ago
View all stories for Ampio Pharmaceuticals | View All Stories
Is Ampio (NYSEMKT:AMPE) catching up with Precision (NASDAQ:DTIL)?
By analyzing existing basic indicators between Ampio Pharmaceuticals and Precision, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Precision with a short position in Ampio Pharmaceuticals. Check out our pair correlation module for more information.

Let's begin by analyzing the assets. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Ampio Pharmaceuticals has an asset utilization ratio of 2.31 percent. This indicates that the company is making $0.0231 for each dollar of assets. An increasing asset utilization means that Ampio Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two companies, such as Ampio or DYADIC is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is Ampio Pharmaceuticals's Liquidity

Ampio Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Ampio Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Ampio Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Ampio Pharmaceuticals's total debt and its cash.

Correlation Between Ampio and DYADIC INTERNATIONAL INC

In general, stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Ampio Pharmaceuticals together with similar or unrelated positions with a negative correlation. For example, you can also add DYADIC INTERNATIONAL to your portfolio. If DYADIC INTERNATIONAL is not perfectly correlated to Ampio Pharmaceuticals it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Ampio Pharmaceuticals for example, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down. Please check pair correlation details between AMPE and DYAI for more information.

A Deeper look at Ampio

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Let me now analyze Ampio Pharmaceuticals revenue. Based on the latest financial disclosure, Ampio Pharmaceuticals reported 1.16 M of revenue. This is 99.98% lower than that of the Healthcare sector and 99.84% lower than that of the Biotechnology industry. The revenue for all United States stocks is 99.99% higher than that of the company. As for Precision BioSciences we see revenue of 21.96 M, which is 97.04% lower than that of the Biotechnology

Sector
742.9 M
AMPE1.16 Million0.15
Sector742.91 Million96.98
DTIL21.96 Million2.87

Over 3 percent surge for Ampio Pharmaceuticals. What does it mean for shareholders?

The variance is down to 85.58 as of today. Ampio Pharmaceuticals is displaying above-average volatility over the selected time horizon. Investors should scrutinize Ampio Pharmaceuticals independently to ensure intended market timing strategies are aligned with expectations about Ampio Pharmaceuticals volatility.

The Current Takeaway on Ampio Pharmaceuticals Investment

Although many of the other players under the biotechnology industry are still a bit expensive, Ampio Pharmaceuticals may offer a potential longer-term growth to shareholders. While some shareholders may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Ampio Pharmaceuticals.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Ampio Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com